Sabine Guth, PhD

Director, Diseases Of Aging and Regenerative Medicine, Biomedical Research, Novartis


E3 ligase and a very selective kinase inhibitor for a BMP-type I receptor, both currently undergoing clinical evaluation. From 2013 to 2023 she was the director of the Joint, Bone and Tendon Research Unit of MSD and since 2023 she leads the in vitro Discovery Unit of “Disease of Aging and Regenerative Medicine” in Biomedical Research, Novartis, Basel.